PURPOSE: To evaluate if two pharmacological agents, Tempol and D-methionine (D-met), are able to prevent oral mucositis in mice after exposure to ionizing radiation ± cisplatin. METHODS AND MATERIALS: Female C3H mice, ∼8 weeks old, were irradiated with five fractionated doses ± cisplatin to induce oral mucositis (lingual ulcers). Just before irradiation and chemotherapy, mice were treated, either alone or in combination, with different doses of Tempol (by intraperitoneal [ip] injection or topically, as an oral gel) and D-met (by gavage). Thereafter, mice were sacrificed and tongues were harvested and stained with a solution of Toluidine Blue. Ulcer size and tongue epithelial thickness were measured. RESULTS: Significant lingual ulcers resulted from 5 × 8 Gy radiation fractions, which were enhanced with cisplatin treatment. D-met provided stereospecific partial protection from lingual ulceration after radiation. Tempol, via both routes of administration, provided nearly complete protection from lingual ulceration. D-met plus a suboptimal ip dose of Tempol also provided complete protection. CONCLUSIONS: Two fairly simple pharmacological treatments were able to markedly reduce chemoradiation-induced oral mucositis in mice. This proof of concept study suggests that Tempol, alone or in combination with D-met, may be a useful and convenient way to prevent the severe oral mucositis that results from head-and-neck cancer therapy. Published by Elsevier Inc.
PURPOSE: To evaluate if two pharmacological agents, Tempol and D-methionine (D-met), are able to prevent oral mucositis in mice after exposure to ionizing radiation ± cisplatin. METHODS AND MATERIALS: Female C3H mice, ∼8 weeks old, were irradiated with five fractionated doses ± cisplatin to induce oral mucositis (lingual ulcers). Just before irradiation and chemotherapy, mice were treated, either alone or in combination, with different doses of Tempol (by intraperitoneal [ip] injection or topically, as an oral gel) and D-met (by gavage). Thereafter, mice were sacrificed and tongues were harvested and stained with a solution of Toluidine Blue. Ulcer size and tongue epithelial thickness were measured. RESULTS: Significant lingual ulcers resulted from 5 × 8 Gy radiation fractions, which were enhanced with cisplatin treatment. D-met provided stereospecific partial protection from lingual ulceration after radiation. Tempol, via both routes of administration, provided nearly complete protection from lingual ulceration. D-met plus a suboptimal ip dose of Tempol also provided complete protection. CONCLUSIONS: Two fairly simple pharmacological treatments were able to markedly reduce chemoradiation-induced oral mucositis in mice. This proof of concept study suggests that Tempol, alone or in combination with D-met, may be a useful and convenient way to prevent the severe oral mucositis that results from head-and-neck cancer therapy. Published by Elsevier Inc.
Authors: Joel B Epstein; Jennifer L Beaumont; Clement K Gwede; Barbara Murphy; Adam S Garden; Ruby Meredith; Quynh-Thu Le; David Brizel; John Isitt; David Cella Journal: Cancer Date: 2007-05-01 Impact factor: 6.860
Authors: Jens Buentzel; Oliver Micke; Irenaus A Adamietz; Alain Monnier; Michael Glatzel; Alexander de Vries Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-21 Impact factor: 7.038
Authors: Saleha B Vuyyuri; Daniel A Hamstra; Divya Khanna; Christin A Hamilton; Sonja M Markwart; Kathleen C M Campbell; Prasad Sunkara; Brian D Ross; Alnawaz Rehemtulla Journal: Clin Cancer Res Date: 2008-04-01 Impact factor: 12.531
Authors: J B Mitchell; W DeGraff; D Kaufman; M C Krishna; A Samuni; E Finkelstein; M S Ahn; S M Hahn; J Gamson; A Russo Journal: Arch Biochem Biophys Date: 1991-08-15 Impact factor: 4.013
Authors: James M Metz; Debbie Smith; Rosemarie Mick; Robert Lustig; James Mitchell; Murali Cherakuri; Eli Glatstein; Stephen M Hahn Journal: Clin Cancer Res Date: 2004-10-01 Impact factor: 12.531
Authors: S M Hahn; F J Sullivan; A M DeLuca; C M Krishna; N Wersto; D Venzon; A Russo; J B Mitchell Journal: Free Radic Biol Med Date: 1997 Impact factor: 7.376
Authors: Ana P Cotrim; Fuminori Hyodo; Ken-Ichiro Matsumoto; Anastasia L Sowers; John A Cook; Bruce J Baum; Murali C Krishna; James B Mitchell Journal: Clin Cancer Res Date: 2007-08-15 Impact factor: 12.531
Authors: Carryn M Anderson; Stephen T Sonis; Christopher M Lee; Douglas Adkins; Bryan G Allen; Wenqing Sun; Sanjiv S Agarwala; Madhavi L Venigalla; Yuhchyau Chen; Weining Zhen; Diane R Mould; Jon T Holmlund; Jeffrey M Brill; John M Buatti Journal: Int J Radiat Oncol Biol Phys Date: 2017-10-16 Impact factor: 7.038
Authors: Alexandros G Georgakilas; Christophe E Redon; Nicholas F Ferguson; Thomas B Kryston; Palak Parekh; Jennifer S Dickey; Asako J Nakamura; James B Mitchell; William M Bonner; Olga A Martin Journal: Cancer Lett Date: 2014-07-25 Impact factor: 8.679
Authors: Letícia de Freitas Cuba; Aroldo Braga Filho; Karen Cherubini; Fernanda Gonçalves Salum; Maria Antonia Zancanaro de Figueiredo Journal: Support Care Cancer Date: 2015-12-23 Impact factor: 3.603
Authors: L Y Teos; C-Y Zheng; X Liu; W D Swaim; C M Goldsmith; A P Cotrim; B J Baum; I S Ambudkar Journal: Gene Ther Date: 2016-03-11 Impact factor: 5.250
Authors: Deborah Citrin; Luca Valle; Kevin Camphausen; Theresa Cooley-Zgela; Deedee Smart; Michael Yao; James B Mitchell; William Thompson; Irini Sereti; Thomas Uldrick Journal: Int J Oncol Date: 2022-04-19 Impact factor: 5.650